GO C15
Alternative Names: GO-C-15Latest Information Update: 10 Feb 2023
At a glance
- Originator GO Therapeutics
- Class Antibodies; Antineoplastics; Cytokines; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Solid tumours
Most Recent Events
- 08 Feb 2023 Early research in Solid tumours in USA (unspecified route) as of February 2023 (Go Therapeutics pipeline, February 2023)
- 29 Jan 2021 G0 C15 is available for licensing as of 29 Jan 2021. https://gotherapeutics.com/partnerships/ (GO Therapeutics pipeline, January 2021)